Arcadia Biosciences (RKDA) AI Stock Analysis

• Market Cap: $6.08M
• Dividend Yield: N/A
• Average Volume (3M): 9.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: -2.81%
• EPS Growth: 72.03%
• Country: US
• Employees: 9
• Sector: Consumer Defensive
• Sector Strength: 67
• Industry: Agricultural Inputs
• EPS (TTM): -3.26
• Shares Outstanding: 1,367,040
• 10 Day Avg. Volume: 3,593
• 30 Day Avg. Volume: 9,007
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.15
• Enterprise Value/Revenue: 0.17
• Enterprise Value/Gross Profit: 0.44
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $4.50
• Price Target Upside: -2.81% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $4.50 ▼(-2.81% Downside)

The overall stock score of 49 reflects significant financial challenges, particularly in profitability and cash flow. While there are positive developments such as Zola's revenue growth and strategic initiatives, the negative valuation metrics and technical indicators weigh heavily. Potential risks from corporate events and the stock's technical position further contribute to the cautious outlook.

Positive Factors

Financial Performance

Q4’24 results were ahead of expectations behind Zola coconut water growth of 124% via an 86% distribution increase.

Market Expansion

Zola’s 80% distribution expansion in 2024 to approximately 3,000 stores is providing considerable visibility for year-over-year growth.

Negative Factors

Portfolio Monetization

Management noted they continue to seek further monetization of legacy ag biotech IP and expect a series of transactions to unwind this portfolio.

Valuation Concern

Arcadia's current valuation levels are considered materially depressed relative to a post-merger fair value, making it an attractive option for special situation and/or merger arbitrage investors.

Arcadia Biosciences Business Overview & Revenue Model

Company Description

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.

How the Company Makes Money

Arcadia Biosciences generates revenue through a combination of product sales, licensing agreements, and collaborations. The company's key revenue streams include the sale of its innovative crop products, such as its high-fiber wheat and omega-3 soybean products, which are marketed to food manufacturers and agricultural producers. Additionally, Arcadia engages in strategic partnerships with other agricultural companies to co-develop products and technologies, which can include upfront payments, milestone payments, and royalties on future sales. The company's focus on sustainability and nutrition has attracted interest from investors and partners, providing a supportive ecosystem for its revenue generation activities.

Arcadia Biosciences Financial Statement Overview

Summary

Arcadia Biosciences is facing financial challenges, particularly with profitability and cash flow generation. Revenue has declined, and the company remains unprofitable, although it has managed to maintain a strong equity position with minimal debt. The company needs to address its operational efficiency and cash flow management to improve its financial stability.

Income Statement

Arcadia Biosciences has faced challenges in maintaining revenue growth and profitability. The revenue decreased slightly from $5.33 million in 2023 to $5.045 million in 2024, indicating a revenue decline of approximately 5.35%. The gross profit margin improved slightly, but the company remains unprofitable with a negative net income for the year ending 2024. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a moderate level of financial stability with a debt-to-equity ratio of 0.025, indicating low leverage. However, the return on equity remains negative due to consistent net losses. The equity ratio is 46%, indicating a solid equity position relative to total assets.

Cash Flow

Arcadia Biosciences experienced substantial free cash flow challenges, with negative free cash flow growth. Operating cash flow to net income ratio is negative, reflecting cash flow difficulties. However, cash flow from investing activities was positive, indicating some level of investment recovery.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.04M	5.33M	9.96M	6.78M	8.03M
Gross Profit	2.08M	2.03M	154.00K	-1.93M	2.83M
EBITDA	-7.50M	-13.58M	-13.65M	-23.27M	-5.44M
Net Income	-7.04M	-13.98M	-15.61M	-16.13M	-6.03M
Balance Sheet
Total Assets	13.52M	19.70M	28.92M	43.92M	47.35M
Cash, Cash Equivalents and Short-Term Investments	4.24M	11.64M	20.64M	28.68M	25.67M
Total Debt	155.00K	1.01M	2.02M	3.29M	9.35M
Total Liabilities	7.29M	7.00M	8.02M	12.72M	18.80M
Stockholders Equity	6.22M	12.84M	21.03M	31.09M	27.73M
Cash Flow
Free Cash Flow	-9.64M	-15.30M	-14.05M	-26.88M	-32.55M
Operating Cash Flow	-9.63M	-15.29M	-13.98M	-25.87M	-30.22M
Investing Cash Flow	7.34M	-4.34M	1.42M	16.61M	17.28M
Financing Cash Flow	9.00K	5.51M	4.52M	21.90M	20.56M

Arcadia Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RKDA, the sentiment is Positive. The current price of 4.63 is above the 20-day moving average (MA) of 4.39, above the 50-day MA of 4.56, and above the 200-day MA of 4.28, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.13 is Neutral, neither overbought nor oversold. The STOCH value of 67.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RKDA.

Arcadia Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$21.01B	14.53	-7.26%	3.13%	3.36%	-7.91%
BIOX	62 Neutral	$199.42M	193.48	-3.00%	―	-13.98%	-403.56%
BHST	56 Neutral	$157.86M	―	-973.22%	―	57.83%	40.94%
RKDA	49 Neutral	$6.08M	―	-7.89%	―	-2.81%	72.03%
LVRO	44 Neutral	$245.67M	―	-69.68%	―	―	―
AVD	43 Neutral	$145.00M	―	-42.97%	0.78%	-9.57%	-3226.39%
SEED	41 Neutral	$7.13M	2.75		―	-21.82%	-104.92%

Arcadia Biosciences Corporate Events

Arcadia Biosciences Faces Payment Default from Above Food

On May 14, 2024, Arcadia Biosciences and its subsidiary sold certain assets of its GoodWheat business to Above Food Corp. and transferred $2 million in cash as part of an Asset Purchase Agreement. In return, Arcadia received a promissory note for $6 million, with payments scheduled over three years. However, as of May 14, 2025, Above Food Corp. failed to make the first payment, leading to a potential default situation. Arcadia is considering actions to enforce its rights under the agreement. Additionally, Arcadia is involved in a proposed all-stock transaction with Roosevelt Resources, which involves the exchange of shares and is subject to regulatory approval.

The most recent analyst rating on (RKDA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.